Residual protein analysis by SDS–PAGE in clinically manufactured BM-MSC products


KILIÇ P., KARABUDAK S., Cosar B., Savran B. N., Yalcin M.

Electrophoresis, 2024 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Publication Date: 2024
  • Doi Number: 10.1002/elps.202300286
  • Journal Name: Electrophoresis
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Aerospace Database, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, EMBASE, Food Science & Technology Abstracts, Metadex, Veterinary Science Database, Civil Engineering Abstracts
  • Keywords: advanced therapy medicinal products, bone marrow-derived mesenchymal stromal/stem cells (BM-MSCs), mesenchymal stromal/stem cells (MSCs), residual protein analysis, sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
  • Middle East Technical University Affiliated: Yes

Abstract

Residual substances that are considered hazardous to the recipient must be removed from final cellular therapeutic products manufactured for clinical purposes. In doing so, quality rules determined by competent authorities (CAs) for the clinical use of tissue- and cell-based products can be met. In our study, we carried out residual substance analyses, and purity determination studies of trypsin and trypsin inhibitor in clinically manufactured bone marrow-derived mesenchymal stromal/stem cell products, using the sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) method. Despite being a semiquantitative method, SDS–PAGE has several benefits over other methods for protein analysis, such as simplicity, convenience of use, and affordability. Due to its convenience and adaptability, SDS–PAGE is still a commonly used method in many laboratories, despite its limits in dynamic range and quantitative precision. Our goal in this work was to show that SDS–PAGE may be used effectively for protein measurement, especially where practicality and affordability are the major factors. The results of our study suggest a validated method to guide tissue and cell manufacturing sites for making use of an agreeable, accessible, and cost-effective method for residual substance analyses in clinically manufactured cellular therapies.